ApoB: The New Lipid Standard
Atherosclerosis is a disease of particle number, not cholesterol mass. Apolipoprotein B (ApoB) provides a direct count of every atherogenic particle in circulation, making it the most predictive lipid marker for cardiovascular disease.
The Flaw of LDL-C
Low-Density Lipoprotein Cholesterol (LDL-C) measures the total weight of cholesterol carried within LDL particles. It does not measure the number of particles. Two patients with identical LDL-C levels of 100 mg/dL can have vastly different risk profiles. One might have a small number of large, cholesterol-rich particles, while the other has a large number of small, cholesterol-depleted particles. The latter patient has a significantly higher risk of atherogenesis, yet LDL-C fails to distinguish between them.
Why ApoB is Superior
Every single atherogenic particle—VLDL, IDL, LDL, and Lp(a)—contains exactly one ApoB molecule. Therefore, an ApoB test is a direct measurement of the total atherogenic particle concentration. Mendelian randomization studies consistently show that the risk of cardiovascular disease tracks with ApoB concentration, even when LDL-C is discordant (e.g., normal LDL-C but high ApoB).
Optimal Targets for Longevity
Standard lab reference ranges often define "normal" ApoB as anything under 90-100 mg/dL. However, "normal" in a population where cardiovascular disease is the leading cause of death is not optimal for longevity.
Target Ranges
- Standard Lab "Normal" < 90 mg/dL
- AHA High-Risk Target < 70 mg/dL
- Longevity / Aggressive Target < 60 mg/dL (Ideally < 50)
Clinical Intervention
When lifestyle interventions (reducing saturated fat intake, increasing soluble fiber) fail to drive ApoB to optimal levels, pharmacological intervention is standard.
- Statins: The first-line therapy. Rosuvastatin and pitavastatin are often preferred for their efficacy and lower risk of muscle-related side effects compared to simvastatin.
- Ezetimibe: Often added as a second-line agent to block cholesterol absorption in the gut. Combination therapy (low-dose statin + ezetimibe) often achieves deeper reductions with fewer side effects than high-dose statin monotherapy.
- PCSK9 Inhibitors: Monoclonal antibodies (e.g., Repatha) used for familial hypercholesterolemia or statin-intolerant patients, capable of profound ApoB reductions.
- Bempedoic Acid: A newer non-statin option acting in the same pathway as statins but strictly in the liver, avoiding muscle side effects.
Note: When html-minifier-terser is applied, we ensure mathematical symbols like < are properly escaped as < to avoid Parse Errors.